WCLC 2019
Read the full Report (pdf)
World Conference on Lung Cancer
07–10 September 2019 Barcelona, Spain
Featured articles
Five-fold increase of OS at 5 years with nivolumab vs docetaxel
CONTENTS
Online First
Screening, Detection, and Diagnosis
Non-Small-Cell Lung Cancer
Five-fold increase of OS at 5 years with nivolumab vs docetaxel
Pembrolizumab + chemotherapy beneficial in advanced NSCLC, even without PD-L1 expression
Promising phase 1 results of novel KRAS-inhibitor in NSCLC
Selpercatinib (LOXO-292) shows durable activity in RET fusion-positive lung cancer
Other Thoracic Malignancies
Novel targets in mesothelioma may aid in developing treatment strategies
Immuno-Oncology
Nivolumab + ipilimumab safe first-line treatment for NSCLC patients with comorbidities
Targeted Therapy
Phase 3 Trial Updates
First-line pembrolizumab monotherapy offers durable OS benefit vs chemotherapy in NSCLC patients with high PD-L1 expression
